|
|
||||||||
RESEARCH REPORTS |
1 Burn and Shock Trauma Institute, and
2 Division of Oral and Maxillofacial Surgery, Department of Surgery, Loyola University Medical Center, 2160 S. First Ave., Maywood, IL 60153;
* corresponding author, ldipiet{at}lumc.edu
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: wound healing angiogenesis VEGF oral mucosa skin
| INTRODUCTION |
|---|
|
|
|---|
Wound angiogenesis follows an orderly pattern, yet its regulation is incompletely understood. Moreover, the precise requirements for wound angiogenesis are not known, since recent studies suggest that wound re-epithelialization can proceed normally even when angiogenesis is partially inhibited (Bloch et al., 2000). Additionally, data regarding the pattern of wound angiogenesis in different anatomic sites, such as oral and dermal locations, are scarce.
The present study examined whether there are site-specific differences in wound angiogenesis. Utilizing a murine model of equivalent excisional dermal and oral mucosal wounds, we determined the pattern of neovascularization and the production of two critical angiogenic factors, VEGF and fibroblast growth factor-2 (FGF-2). In addition, we examined VEGF mRNA and protein levels in vitro in human oral and epidermal keratinocytes, since these cells are a major source of VEGF in healing wounds.
| MATERIALS & METHODS |
|---|
|
|
|---|
Analysis of Wound Vascularization
Ten-µm sections were stained with an endothelial cell-specific monoclonal antibody to CD31 (PharMingen, San Diego, CA, USA) and counterstained with Harris hematoxylin (Sigma, St. Louis, MO, USA) as previously described (Swift et al., 1999). Sections were imaged by Optronics Acquisition software (Optronics Engineering, Goleta, CA, USA) and analyzed by ScionImage software (Scion Corp., Frederick, MD, USA). Using a freehand drawing tool, we outlined the wound bed and measured the wound area. Only the CD31-positive area within the wound bed was identified with a colorization tool in the software; vessel lumens were not colorized. Most vessels were capillaries with lumens of negligible size. At each time point, the % vascularization [CD31-positive area/Total wound bed area) x 100] was determined for 2 wound sections from each of 5 mice. We determined the increase in vascularization in the wound bed over the normal tissue by dividing by baseline values.
Analysis of Growth Factors in Wounds
VEGF and FGF-2 levels in wounds were determined by murine VEGF and human FGF-2-specific ELISA kits (R&D Systems, Minneapolis, MN, USA). The human FGF-2-specific ELISA kit (R&D Systems) has been previously shown to react with murine FGF-2 (Swift et al., 1999; Szpaderska et al., 2003). Briefly, wounds were excised by means of a 3-mm Acu-Punch and homogenized in 1.0 mL of PBS containing Complete Protease Inhibitor Cocktail (Roche, Indianapolis, IN, USA). Homogenates were centrifuged and filtered through a 1.2-µm-pore filter. The growth factor levels were normalized to protein concentration.
Keratinocyte Isolation and Cell Culture
Keratinocytes were cultured at 37°C and 5% CO2 in a humid atmosphere. Human adult skin keratinocytes were purchased from Clonetics and grown in keratinocyte basal medium-2, KBM-2 (Cambrex, Walkersville, MD, USA). Human oral mucosal tissue was obtained from healthy donors (age 1525 yrs), after consent under a protocol approved by the Loyola University (Chicago) Institutional Review Board. Primary keratinocytes were isolated by a standard protocol that allows for the establishment of keratinocytes free of other cell types (Oda and Watson, 1990). The tissues were washed with PBS containing 50 µg/mL gentamycin and 0.5 µg/mL amphotericin B, and incubated overnight at 4°C with dispase solution (calcium- and magnesium-free PBS containing 25.0 caseinolytic U/mL dispase and 5 µg/mL gentamycin). Separated epithelium was incubated for 15 min at 37°C in 0.05% trypsin and 0.53 mM EDTA (Invitrogen, Carlsbad, CA, USA) so that a single cell suspension would be prepared. Following incubation, trypsin was neutralized with PBS containing 10 mg/mL Soybean Trypsin Inhibitor (Invitrogen, Carlsbad, CA, USA). The cell pellet was collected by centrifugation for 3 min at 700 rpm and re-suspended in KBM-2. Primary keratinocytes were seeded at a density of 3 x 106 cells per 75-cm2 flask. At 75% confluence, KBM-2 was aspirated, and 1 mL of trypsin/EDTA solution was added. Cells were incubated for 10 min at 37°C, trypsin inhibitor was added, and the cell suspension was centrifuged for 3 min at 700 rpm. The cells were re-suspended in KBM-2 and transferred into a 60-mm Petri dish at a density of 1 x 105 cells per dish.
Analysis of VEGF Protein and mRNA in Keratinocytes
Skin and oral mucosal keratinocytes were plated in 6-well plates at a density of 1 x 105 cells/well in KBM-2 and incubated overnight. The following day, the plates were incubated for 18 hrs in hypoxic conditions. Hypoxia was generated in a tightly sealed chamber by means of AnaeroGen and assessed by Anerobic Indicator (Oxoid Ltd., Hampshire, England). Typically, the oxygen level in the chamber was reduced to below 1% within 30 min. The simultaneously generated carbon dioxide level was between 9% and 13%. For VEGF protein analysis, medium was removed, centrifuged at 1000 g for 10 min at 4°C, and immediately frozen at 80°C. A Quantikine Human VEGF Immunoassay kit (R&D Systems, Minneapolis, MN, USA) was used to detect VEGF in culture supernatants. The cells were washed with PBS, detached with trypsin/EDTA, centrifuged at 1000 g for 3 min at 4°C, and re-suspended in PBS. Cell viability, determined by trypan-blue staining, was over 90% in all conditions. No evidence of death could be detected in cultures exposed to hypoxia, and cells continued to proliferate at a normal rate if re-exposed to normal oxygen tension. The experiment was done in triplicate.
For mRNA analysis, keratinocytes were rinsed with PBS and underwent lysis in TRI REAGENT (Sigma, St. Louis, MO, USA) according to the manufacturers instructions. Total RNA was isolated and treated with DNase I (Invitrogen, Carlsbad, CA, USA); reverse transcription was performed with Omniscript Reverse Transcriptase (Qiagen, Valencia, CA, USA) and an oligo-dT primer (Amersham Pharmacia, Piscataway, NJ, USA), as described previously (Szpaderska et al., 2003). The optimal number of PCR cycles for each gene was determined. PCR products were separated by gel electrophoresis and scanned by densitometry. Densitometry values of the 493-bp PCR product corresponding to VEGF165 were normalized to ß-actin expression at each time point and compared with the highest value set to 100. Primer sequences were: VEGF (NM_003376) 5'TGGGTGCATT GGAGCCTTGCCTTGCTGCTC3', 5'TCTGGTTCCCGAAA CCCTGAGGGAGGCTCC3', ß-actin (X03672): 5'GTGGGCCG CCCTAGGCACCA3', and 5'CTCTTTGATGTCACGCACG ATTTC3'.
Statistical Analysis
The mean and standard error of the mean were calculated for each experimental group. Data described over time were analyzed by two-way ANOVA, followed by the Newman-Keuls post hoc test. Data described at single time points were analyzed by an unpaired t test.
| RESULTS |
|---|
|
|
|---|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
The requirement for angiogenesis in wounds remains controversial. However, one recent study suggests that robust angiogenesis supports scar formation. In this study, endostatin, administered subcutaneously to mice, led to impaired vessel integrity and reduced granulation tissue in excisional wounds. Scarring was slightly reduced, and the deposited collagen appeared less dense, demonstrating that endostatin treatment could improve the quality of the healed wound (Bloch et al., 2000).
Our findings suggest that wounds with superior healing, such as oral mucosal injuries, may exhibit less robust neovascularization. Oral wounds heal quickly, and generally exhibit less scar formation than dermal wounds. Analysis of our data supports the hypothesis that robust angiogenesis seen in dermal wounds supports scar formation. The more modest angiogenesis observed in oral mucosal wounds may keep the fibrotic response in oral tissues in check by reducing available nutrient support.
The mechanism by which angiogenesis is regulated in oral tissues remains to be elucidated. However, our studies suggest that decreased production of VEGF may be a factor. Among the 30 or more known pro-angiogenic factors, VEGF has been shown to be the dominant mediator of wound angiogenesis (Nissen et al., 1998). In normal skin, VEGF is expressed at low levels, whereas its expression is highly up-regulated in keratinocytes during healing (Berse et al., 1992; Brown et al., 1992; Kishimoto et al., 2000). Our findings demonstrate that VEGF production in oral wounds lags behind the levels seen in skin. It has been suggested that the presence of VEGF in salivary glands and saliva may facilitate the high healing capacity shown by oral tissues (Pammer et al., 1998; Taichman et al., 1998). Despite the presence of VEGF in saliva, our studies indicate that the levels of VEGF within the wound are lower in oral than in cutaneous injuries at all time points. Similarly, our previous studies demonstrated that expression of TGF-ß, another pro-angiogenic growth factor, is lower in oral wounds than in skin wounds (Szpaderska et al., 2003). However, the site-related decrease in growth factors does not seem to be global, since no differences in FGF-2 levels were seen in oral and skin wounds. These findings suggest that oral mucosal wounds are characterized by a lower expression of some, but not all, pro-angiogenic factors than are skin wounds. Both VEGF and FGF-2 levels were very similar in oral mucosal and skin wounds 7 days after injury. However, vessel density was lower in oral wounds as compared with skin at this time point. This difference in angiogenesis may be due to the presence of other pro-angiogenic factors in the skin that we did not investigate. Since wound angiogenesis is dictated by the equilibrium between pro- and anti-angiogenic factors, the oral wounds may also have higher levels of inhibitors of capillary growth.
In the skin, migrating keratinocytes at the wound edge express high levels of VEGF, suggesting that keratinocyte-derived VEGF stimulates angiogenesis during wound healing (Brown et al., 1992; Ballaun et al., 1995; Detmar et al., 1995; Frank et al., 1995; Viac et al., 1997). Results from the present study suggest that VEGF gene expression and protein production differ in oral and epidermal keratinocytes. Following a hypoxic stimulus, VEGF mRNA and protein levels increased about 2-fold, while epidermal keratinocytes exhibited a 3- to 4-fold increase. These intrinsic differences may represent at least part of the mechanism of reduced wound angiogenesis at oral sites.
Taken together, our studies and those of others suggest that, in normal wound closure, robust angiogenesis may be in excess of physiologic needs, and may in fact support scar formation. This hypothesis does not deny that a certain level of angiogenesis is likely required for optimal healing. Additional studies are necessary for full understanding of the significance and mechanism behind the site-specific differences in angiogenesis in oral mucosal and skin wounds.
| ACKNOWLEDGMENTS |
|---|
Received February 9, 2004; Last revision January 5, 2005; Accepted January 12, 2005
| REFERENCES |
|---|
|
|
|---|
Berger AC, Feldman AL, Gnant MF, Kruger EA, Sim BK, Hewitt S, et al. (2000). The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. J Surg Res 91:2631.[ISI][Medline]
Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR (1992). Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3:211220.[Abstract]
Bloch W, Huggel K, Sasaki T, Grose R, Bugnon P, Addicks K, et al. (2000). The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J 14:23732376.
Brakenhielm E, Cao R, Cao Y (2001). Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 15:17981800.
Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF, et al. (1992). Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 176:13751379.
Detmar M, Yeo KT, Nagy JA, Van de Water L, Brown LF, Berse B, et al. (1995). Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol 105:4450.[ISI][Medline]
Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG, Werner S (1995). Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 270:1260712613.
Kishimoto J, Ehama R, Ge Y, Kobayashi T, Nishiyama T, Detmar M, et al. (2000). In vivo detection of human vascular endothelial growth factor promoter activity in transgenic mouse skin. Am J Pathol 157:103110.
Klein SA, Bond SJ, Gupta SC, Yacoub OA, Anderson GL (1999). Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing. J Surg Res 82:268274.[ISI][Medline]
Knighton DR, Silver IA, Hunt TK (1981). Regulation of wound-healing angiogenesiseffect of oxygen gradients and inspired oxygen concentration. Surgery 90:262270.[ISI][Medline]
Mundhenke C, Thomas JP, Wilding G, Lee FT, Kelzc F, Chappell R, et al. (2001). Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res 7:33663374.
Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA (1998). Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 152:14451452.[Abstract]
Oda D, Watson E (1990). Human oral epithelial cell culture I. Improved conditions for reproducible culture in serum-free medium. In Vitro Cell Dev Biol 26:589595.[ISI][Medline]
Pammer J, Weninger W, Mildner M, Burian M, Wojta J, Tschachler E (1998). Vascular endothelial growth factor is constitutively expressed in normal human salivary glands and is secreted in the saliva of healthy individuals. J Pathol 186:186191.[ISI][Medline]
Roman CD, Choy H, Nanney L, Riordan C, Parman K, Johnson D, et al. (2002). Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 105:4347.[ISI][Medline]
Swift ME, Kleinman HK, DiPietro LA (1999). Impaired wound repair and delayed angiogenesis in aged mice. Lab Invest 79:14791487.[ISI][Medline]
Szpaderska AM, Zuckerman JD, DiPietro LA (2003). Differential injury responses in oral mucosal and cutaneous wounds. J Dent Res 82:621626.
Taichman NS, Cruchley AT, Fletcher LM, Hagi-Pavli EP, Paleolog EM, Abrams WR, et al. (1998). Vascular endothelial growth factor in normal human salivary glands and saliva: a possible role in the maintenance of mucosal homeostasis. Lab Invest 78:869875.[ISI][Medline]
Tanaka H, Taniguchi H, Mugitani T, Koishi Y, Masuyama M, Koyama H, et al. (1996). Angiogenesis inhibitor TNP-470 prevents implanted liver metastases after partial hepatectomy in an experimental model without impairing wound healing. Br J Surg 83:14441447.[ISI][Medline]
te Velde EA, Kusters B, Maass C, de Waal R, Borel Rinkes IH (2003). Histological analysis of defective colonic healing as a result of angiostatin treatment. Exp Mol Pathol 75:119123.[ISI][Medline]
Viac J, Palacio S, Schmitt D, Claudy A (1997). Expression of vascular endothelial growth factor in normal epidermis, epithelial tumors and cultured keratinocytes. Arch Dermatol Res 289:158163.[ISI][Medline]
This article has been cited by other articles:
![]() |
Y. Nakase, T. Nakamura, S. Kin, S. Nakashima, T. Yoshikawa, Y. Kuriu, C. Sakakura, H. Yamagishi, J. Hamuro, Y. Ikada, et al. Intrathoracic esophageal replacement by in situ tissue-engineered esophagus. J. Thorac. Cardiovasc. Surg., October 1, 2008; 136(4): 850 - 859. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| IADR Journals | Advances in Dental Research ® |
| Journal of Dental Research ® | Critical Reviews (1990-2004) |